A readjudication of mortality data from the FOURIER trial by outside researchers concludes CV death was higher with evolocumab than originally reported. But FOURIER trialists stand by their conclusions.
A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.
The FDA placed a clinical hold on Verve Therapeutics’ application to begin human testing of its gene-editing therapy for an inherited form of high cholesterol. No details about the FDA’s questions or concerns were disclosed; so far, no serious safety problems have been reported in the U.K. and New Zealand where the clinical trial is already underway.
The powerful LDL-lowering agents aren t being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.